Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
AvroBio
Biotech
Avrobio hopes to get investors back on gene therapy bandwagon
It’s been a year since Avrobio's Fabry disease program failed. Now, the biotech is ready to reintroduce itself.
Annalee Armstrong
Dec 7, 2022 7:30am
Avrobio CEO shares outlook on cell and gene landscape
Sep 30, 2022 12:02pm
Avrobio gene therapy shows signs of durability in rare disorder
Feb 9, 2022 10:46am
Avrobio ditches Fabry, eyes 2023 trials for other gene therapies
Jan 4, 2022 10:08am
Avrobio plans Fabrazyme trial after FDA changes path to market
May 3, 2021 8:55am
Avrobio gene therapy eliminates toxic substrate in Fabry patient
Feb 8, 2021 8:40am
